BiotechTube
AmbioPharm

AmbioPharm

North Augusta, United States· Est.
ambiopharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AmbioPharm is a leading, privately-held peptide CDMO with one of the world's largest dedicated peptide manufacturing capacities. It provides end-to-end services for pharmaceutical and biotech clients, focusing on accelerating peptides from Phase II trials to commercialization. The company's business model emphasizes scalable production, regulatory expertise, and cost efficiency across its dual-geography operations in the United States and China.

Small MoleculesDrug Delivery

Technology Platform

Mastery of multiple peptide synthesis methodologies (Solid Phase, Liquid Phase, Hybrid), coupled with comprehensive analytical development and validation services, operating within FDA-inspected facilities in the US and China.

Opportunities

The global peptide therapeutics market is growing rapidly, driving increased demand for specialized, large-scale API manufacturing.
AmbioPharm's recent capacity expansion and dual-source (US & China) model position it to capture a significant share of this outsourced demand, particularly for late-stage and commercial projects.

Risk Factors

Key risks include operational/regulatory failure at its manufacturing sites, intense competition from other peptide CDMOs pressuring margins, and geopolitical tensions that could disrupt its integrated US-China supply chain and operations.

Competitive Landscape

AmbioPharm competes in the peptide CDMO space against large, established players like Bachem, PolyPeptide Group, and CordenPharma, as well as numerous smaller specialists. Its competitive advantages are its stated large-scale capacity, cost-effective model, regulatory track record, and flexible synthesis expertise.

More companies in Biologics / Biosimilars →More companies in United States →